Symbols / CGEM
CGEM Chart
About
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 829.73M |
| Enterprise Value | 511.61M | Income | -216.81M | Sales | — |
| Book/sh | 7.64 | Cash/sh | 5.63 | Dividend Yield | — |
| Payout | 0.00% | Employees | 111 | IPO | — |
| P/E | — | Forward P/E | -4.27 | PEG | — |
| P/S | — | P/B | 1.84 | P/C | — |
| EV/EBITDA | -2.12 | EV/Sales | — | Quick Ratio | 10.15 |
| Current Ratio | 10.45 | Debt/Eq | 0.26 | LT Debt/Eq | — |
| EPS (ttm) | -3.32 | EPS next Y | -3.29 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -26.53% |
| ROE | -40.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 59.08M |
| Shs Float | 41.96M | Short Float | 15.62% | Short Ratio | 11.71 |
| Short Interest | — | 52W High | 14.35 | 52W Low | 5.68 |
| Beta | -0.10 | Avg Volume | 1.00M | Volume | 400.12K |
| Target Price | $30.63 | Recom | Strong_buy | Prev Close | $14.27 |
| Price | $14.04 | Change | -1.58% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$30.63
Mean price target
2. Current target
$14.27
Latest analyst target
3. DCF / Fair value
$-30.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.27
Low
$22.00
High
$38.00
Mean
$30.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | init | Citigroup | — → Buy | $33 |
| 2026-02-02 | init | Guggenheim | — → Buy | $30 |
| 2026-01-08 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-12-09 | main | Wedbush | Outperform → Outperform | $34 |
| 2025-11-20 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-09-10 | reit | BTIG | Buy → Buy | $32 |
| 2025-08-18 | main | Morgan Stanley | Overweight → Overweight | $28 |
| 2025-05-12 | main | UBS | Buy → Buy | $24 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-02-28 | main | Stifel | Buy → Buy | $19 |
| 2024-10-24 | init | UBS | — → Buy | $30 |
| 2024-08-09 | reit | Wedbush | Outperform → Outperform | $36 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-05-16 | main | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-05-16 | reit | Wedbush | Outperform → Outperform | $36 |
| 2024-05-01 | init | Stifel | — → Buy | $40 |
| 2024-04-17 | main | BTIG | Buy → Buy | $30 |
- Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat Mon, 23 Feb 2026 22
- The Technical Signals Behind (CGEM) That Institutions Follow - Stock Traders Daily Mon, 23 Feb 2026 20
- Top Cullinan Executives Quietly Unload Shares in a Flurry of Insider Sales - TipRanks ue, 24 Feb 2026 02
- $CGEM stock is up 14% today. Here's what we see in our data. - Quiver Quantitative Fri, 31 Oct 2025 07
- Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Lowered by Zacks Research - MarketBeat Sat, 21 Feb 2026 11
- Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers - Seeking Alpha Wed, 28 Jan 2026 08
- Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Yahoo Finance Mon, 15 Dec 2025 08
- Insider Sale: Chief Scientific Officer of $CGEM Sells 4,000 Shares | CGEM Stock News - Quiver Quantitative Fri, 23 Jan 2026 08
- Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) CFO Sells 4,398 Shares of Stock - MarketBeat Mon, 23 Feb 2026 22
- Cullinan Therapeutics: Worthy Of A Small Position - Seeking Alpha Fri, 17 Oct 2025 07
- Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely? - Yahoo Finance Wed, 17 Dec 2025 08
- $CGEM stock is up 34% today. Here's what we see in our data. - Quiver Quantitative Mon, 24 Nov 2025 08
- Cullinan Therapeutics (NASDAQ:CGEM) Insider Jeffrey Alan Jones Sells 4,982 Shares - MarketBeat Mon, 23 Feb 2026 22
- Cullinan Therapeutics (NASDAQ:CGEM) Insider Jacquelyn Sumer Sells 3,742 Shares - MarketBeat Mon, 23 Feb 2026 22
- CULLINAN ONCOLOGY Earnings Results: $CGEM Reports Quarterly Earnings - Quiver Quantitative hu, 06 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8000 | 34400 | — | Conversion of Exercise of derivative security at price 4.30 per share. | MICHAELSON JENNIFER | Officer | — | 2026-02-20 00:00:00 | D |
| 1 | 4398 | 59901 | — | Sale at price 13.62 per share. | FENTON MARY KAY | Chief Financial Officer | — | 2026-02-20 00:00:00 | D |
| 2 | 16381 | 223109 | — | Sale at price 13.62 per share. | AHMED NADIM | Chief Executive Officer | — | 2026-02-20 00:00:00 | D |
| 3 | 11742 | 165366 | — | Sale at price 13.62 - 14.30 per share. | MICHAELSON JENNIFER | Officer | — | 2026-02-20 00:00:00 | D |
| 4 | 3742 | 50966 | — | Sale at price 13.62 per share. | SUMER JACQUELYN L | Officer | — | 2026-02-20 00:00:00 | D |
| 5 | 4982 | 67855 | — | Sale at price 13.62 per share. | JONES JEFFREY ALAN | Officer | — | 2026-02-20 00:00:00 | D |
| 6 | 68750 | — | — | Stock Award(Grant) at price 0.00 per share. | FENTON MARY KAY | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 7 | 57500 | — | — | Stock Award(Grant) at price 0.00 per share. | MICHAELSON JENNIFER | Officer | — | 2026-02-18 00:00:00 | D |
| 8 | 416 | 5004 | — | Sale at price 12.03 per share. | MICHAELSON JENNIFER | Officer | — | 2026-02-12 00:00:00 | D |
| 9 | 4000 | 49200 | — | Sale at price 12.30 per share. | MICHAELSON JENNIFER | Officer | — | 2026-01-22 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -36.74K | 76.97M | 0.00 |
| TaxRateForCalcs | 0.21 | 0.08 | 0.28 | 0.00 |
| NormalizedEBITDA | -196.61M | -189.90M | -408.83M | -67.90M |
| TotalUnusualItems | 0.00 | -440.00K | 276.79M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -440.00K | 276.79M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -167.38M | -153.16M | 111.21M | -65.57M |
| ReconciledDepreciation | 306.00K | 310.00K | 93.00K | 53.00K |
| EBITDA | -196.61M | -190.34M | -132.04M | -67.90M |
| EBIT | -196.92M | -190.65M | -132.14M | -67.95M |
| NetInterestIncome | 29.66M | 21.63M | 6.61M | 477.00K |
| InterestIncome | 29.66M | 21.63M | 6.61M | 477.00K |
| NormalizedIncome | -167.38M | -152.76M | -88.60M | -65.57M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -167.38M | -153.16M | 111.21M | -65.57M |
| TotalExpenses | 196.92M | 190.65M | 132.14M | 86.90M |
| TotalOperatingIncomeAsReported | -196.92M | -191.09M | 144.65M | -67.95M |
| DilutedAverageShares | 53.77M | 41.55M | 46.64M | 43.08M |
| BasicAverageShares | 53.77M | 41.55M | 45.16M | 43.08M |
| DilutedEPS | -2.78 | -3.21 | 2.38 | -1.52 |
| BasicEPS | -2.78 | -3.21 | 2.46 | -1.52 |
| DilutedNIAvailtoComStockholders | -167.38M | -153.16M | 111.21M | -65.57M |
| NetIncomeCommonStockholders | -167.38M | -153.16M | 111.21M | -65.57M |
| NetIncome | -167.38M | -153.16M | 111.21M | -65.57M |
| MinorityInterests | 192.00K | 1.94M | 2.02M | 1.92M |
| NetIncomeIncludingNoncontrollingInterests | -167.57M | -155.10M | 109.19M | -67.48M |
| NetIncomeContinuousOperations | -167.57M | -155.10M | 109.19M | -67.48M |
| TaxProvision | 117.00K | -14.12M | 42.12M | 0.00 |
| PretaxIncome | -167.46M | -169.22M | 151.32M | -67.48M |
| OtherIncomeExpense | -199.00K | -201.00K | 276.84M | -8.00K |
| OtherNonOperatingIncomeExpenses | -199.00K | 239.00K | 57.00K | -8.00K |
| SpecialIncomeCharges | 0.00 | -440.00K | 276.79M | 0.00 |
| GainOnSaleOfBusiness | 0.00 | 276.79M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 440.00K | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 29.66M | 21.63M | 6.61M | 477.00K |
| InterestIncomeNonOperating | 29.66M | 21.63M | 6.61M | 477.00K |
| OperatingIncome | -196.92M | -190.65M | -132.14M | -67.95M |
| OperatingExpense | 196.92M | 190.65M | 132.14M | 86.90M |
| ResearchAndDevelopment | 142.90M | 148.16M | 91.95M | 57.75M |
| SellingGeneralAndAdministration | 54.02M | 42.49M | 40.19M | 29.15M |
| GeneralAndAdministrativeExpense | 54.02M | 42.49M | 40.19M | 29.15M |
| OtherGandA | 54.02M | 42.49M | 40.19M | 29.15M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 18.94M |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 18.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 58.51M | 42.90M | 45.80M | 44.29M |
| ShareIssued | 58.51M | 42.90M | 45.80M | 44.29M |
| TotalDebt | 2.15M | 3.59M | 5.19M | 0.00 |
| TangibleBookValue | 590.33M | 453.70M | 535.03M | 424.97M |
| InvestedCapital | 590.33M | 453.70M | 535.21M | 424.97M |
| WorkingCapital | 384.02M | 452.05M | 451.97M | 284.82M |
| NetTangibleAssets | 590.33M | 453.70M | 535.03M | 424.97M |
| CapitalLeaseObligations | 2.15M | 3.59M | 5.01M | 0.00 |
| CommonStockEquity | 590.33M | 453.70M | 535.03M | 424.97M |
| TotalCapitalization | 590.33M | 453.70M | 535.03M | 424.97M |
| TotalEquityGrossMinorityInterest | 590.33M | 453.89M | 535.03M | 425.37M |
| MinorityInterest | 0.00 | 192.00K | 0.00 | 403.00K |
| StockholdersEquity | 590.33M | 453.70M | 535.03M | 424.97M |
| GainsLossesNotAffectingRetainedEarnings | -133.00K | -129.00K | -2.60M | -838.00K |
| OtherEquityAdjustments | -133.00K | -129.00K | -2.60M | -838.00K |
| RetainedEarnings | -368.24M | -200.86M | -47.70M | -158.91M |
| AdditionalPaidInCapital | 958.70M | 654.68M | 585.32M | 584.71M |
| CapitalStock | 6.00K | 4.00K | 5.00K | 4.00K |
| CommonStock | 6.00K | 4.00K | 5.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 31.50M | 30.29M | 26.09M | 11.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 849.00K | 2.15M | 3.59M | 65.00K |
| NonCurrentDeferredLiabilities | 0.00 | 65.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 849.00K | 2.15M | 3.59M | 0.00 |
| LongTermCapitalLeaseObligation | 849.00K | 2.15M | 3.59M | 0.00 |
| CurrentLiabilities | 30.65M | 28.14M | 22.50M | 11.75M |
| OtherCurrentLiabilities | 1.44M | 914.00K | 1.96M | 973.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.30M | 1.44M | 1.60M | |
| CurrentCapitalLeaseObligation | 1.30M | 1.44M | 1.42M | 0.00 |
| CurrentDebt | 178.00K | |||
| OtherCurrentBorrowings | 178.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.94M | 6.99M | 4.52M | 2.58M |
| PayablesAndAccruedExpenses | 17.97M | 18.80M | 14.43M | 8.20M |
| CurrentAccruedExpenses | 10.30M | 8.43M | 7.49M | 5.03M |
| Payables | 7.68M | 10.36M | 6.94M | 3.17M |
| OtherPayable | 5.99M | 7.87M | ||
| TotalTaxPayable | 0.00 | 4.28M | 0.00 | |
| IncomeTaxPayable | 0.00 | 4.28M | 0.00 | |
| AccountsPayable | 1.68M | 2.49M | 2.66M | 3.17M |
| TotalAssets | 621.82M | 484.18M | 561.12M | 437.19M |
| TotalNonCurrentAssets | 207.16M | 3.99M | 86.64M | 140.62M |
| OtherNonCurrentAssets | 366.00K | 459.00K | 459.00K | 147.00K |
| InvestmentsAndAdvances | 204.44M | 0.00 | 80.88M | 140.40M |
| InvestmentinFinancialAssets | 0.00 | 80.88M | ||
| HeldToMaturitySecurities | 0.00 | 80.88M | ||
| NetPPE | 2.35M | 3.53M | 5.30M | 77.00K |
| AccumulatedDepreciation | -658.00K | -352.00K | -135.00K | -232.00K |
| GrossPPE | 3.01M | 3.88M | 5.44M | 309.00K |
| Leases | 576.00K | 576.00K | 628.00K | 105.00K |
| OtherProperties | 1.67M | 2.54M | 4.13M | |
| MachineryFurnitureEquipment | 765.00K | 765.00K | 681.00K | 204.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 414.67M | 480.19M | 474.47M | 296.56M |
| OtherCurrentAssets | 15.69M | 13.12M | 7.18M | 6.10M |
| PrepaidAssets | 6.10M | |||
| CashCashEquivalentsAndShortTermInvestments | 398.98M | 467.07M | 467.29M | 290.47M |
| OtherShortTermInvestments | 315.97M | 368.63M | 311.14M | 230.69M |
| CashAndCashEquivalents | 83.00M | 98.43M | 156.15M | 59.77M |
| CashEquivalents | 23.85M | |||
| CashFinancial | 35.92M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -145.30M | -134.48M | -127.80M | -43.43M |
| RepaymentOfDebt | 0.00 | -2.20M | 0.00 | |
| IssuanceOfDebt | 0.00 | 1.82M | 2.38M | 0.00 |
| IssuanceOfCapitalStock | 262.65M | 38.39M | 0.00 | 267.27M |
| CapitalExpenditure | -208.00K | -1.13M | ||
| InterestPaidSupplementalData | 32.00K | 0.00 | ||
| IncomeTaxPaidSupplementalData | 37.80M | 0.00 | ||
| EndCashPosition | 83.00M | 98.43M | 156.15M | 59.77M |
| BeginningCashPosition | 98.43M | 156.15M | 59.77M | 168.20M |
| ChangesInCash | -15.43M | -57.72M | 96.38M | -108.42M |
| FinancingCashFlow | 266.19M | 40.75M | -25.93M | 268.78M |
| CashFlowFromContinuingFinancingActivities | 266.19M | 40.75M | -25.93M | 268.78M |
| NetOtherFinancingCharges | -4.45M | -32.13M | -1.76M | |
| ProceedsFromStockOptionExercised | 7.98M | 538.00K | 6.02M | 3.28M |
| NetCommonStockIssuance | 262.65M | 38.39M | 0.00 | 267.27M |
| CommonStockIssuance | 262.65M | 38.39M | 0.00 | 267.27M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.82M | 175.00K | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 1.82M | 175.00K | 0.00 |
| LongTermDebtPayments | 0.00 | -2.20M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 1.82M | 2.38M | 0.00 |
| InvestingCashFlow | -136.31M | 35.81M | 248.97M | -333.77M |
| CashFlowFromContinuingInvestingActivities | -136.31M | 35.81M | 248.97M | -333.77M |
| NetInvestmentPurchaseAndSale | -136.31M | 36.01M | -24.98M | -333.77M |
| SaleOfInvestment | 584.82M | 409.40M | 352.93M | 192.04M |
| PurchaseOfInvestment | -721.13M | -373.38M | -377.92M | -525.81M |
| NetBusinessPurchaseAndSale | 0.00 | 275.00M | 0.00 | |
| SaleOfBusiness | 0.00 | 275.00M | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | -208.00K | -1.04M | 0.00 |
| SaleOfPPE | 0.00 | 91.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -208.00K | -1.13M | 0.00 |
| OperatingCashFlow | -145.30M | -134.28M | -126.66M | -43.43M |
| CashFlowFromContinuingOperatingActivities | -145.30M | -134.28M | -126.66M | -43.43M |
| ChangeInWorkingCapital | -389.00K | -339.00K | 11.18M | -3.54M |
| ChangeInOtherCurrentAssets | 0.00 | |||
| ChangeInPayablesAndAccruedExpense | 2.08M | 5.61M | 12.31M | -272.00K |
| ChangeInAccruedExpense | 2.90M | 10.05M | 8.53M | 4.56M |
| ChangeInPayable | -812.00K | -4.45M | 3.77M | -4.83M |
| ChangeInAccountPayable | -812.00K | -167.00K | -509.00K | -4.83M |
| ChangeInTaxPayable | 0.00 | -4.28M | 4.28M | 0.00 |
| ChangeInIncomeTaxPayable | 0.00 | -4.28M | 4.28M | 0.00 |
| ChangeInPrepaidAssets | -2.47M | -5.94M | -1.13M | -3.27M |
| OtherNonCashItems | 131.00K | 374.00K | 67.00K | |
| StockBasedCompensation | 37.82M | 30.44M | 27.96M | 24.38M |
| AssetImpairmentCharge | 0.00 | 440.00K | 0.00 | |
| AmortizationOfSecurities | -15.47M | -10.15M | 1.29M | 3.10M |
| DepreciationAmortizationDepletion | 306.00K | 310.00K | 93.00K | 53.00K |
| DepreciationAndAmortization | 306.00K | 310.00K | 93.00K | 53.00K |
| OperatingGainsLosses | -276.75M | |||
| GainLossOnInvestmentSecurities | 109.00K | |||
| GainLossOnSaleOfPPE | 0.00 | -77.00K | 0.00 | |
| GainLossOnSaleOfBusiness | 0.00 | -276.79M | 0.00 | |
| NetIncomeFromContinuingOperations | -167.57M | -155.10M | 109.19M | -67.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CGEM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|